Synageva BioPharma Corp. - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 35 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Synageva BioPharma Corp. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Synageva BioPharma Corp. - Product Pipeline Review - 2014', provides an overview of the Synageva BioPharma Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Synageva BioPharma Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Synageva BioPharma Corp. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Synageva BioPharma Corp.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Synageva BioPharma Corp.'s pipeline products

Reasons to buy

- Evaluate Synageva BioPharma Corp.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Synageva BioPharma Corp. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Synageva BioPharma Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Synageva BioPharma Corp. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Synageva BioPharma Corp.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Synageva BioPharma Corp. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Synageva BioPharma Corp. Snapshot 5
Synageva BioPharma Corp. Overview 5
Key Information 5
Key Facts 5
Synageva BioPharma Corp. - Research and Development Overview 6
Key Therapeutic Areas 6
Synageva BioPharma Corp. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Synageva BioPharma Corp. - Pipeline Products Glance 10
Synageva BioPharma Corp. - Late Stage Pipeline Products 10
Phase III Products/Combination Treatment Modalities 10
Synageva BioPharma Corp. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Synageva BioPharma Corp. - Drug Profiles 12
sebelipase alfa 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Multiple New Programs 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
SBC-103 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
SBC-104 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
SBC-105 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
SBC-106 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
SBC-204 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
SBC-238 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Synageva BioPharma Corp. - Pipeline Analysis 21
Synageva BioPharma Corp. - Pipeline Products by Target 21
Synageva BioPharma Corp. - Pipeline Products by Route of Administration 22
Synageva BioPharma Corp. - Pipeline Products by Molecule Type 23
Synageva BioPharma Corp. - Recent Pipeline Updates 24
Synageva BioPharma Corp. - Dormant Projects 31
Synageva BioPharma Corp. - Discontinued Pipeline Products 32
Discontinued Pipeline Product Profiles 32
TRI-999 32
Synageva BioPharma Corp. - Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35

List of Tables
Synageva BioPharma Corp., Key Information 5
Synageva BioPharma Corp., Key Facts 5
Synageva BioPharma Corp. - Pipeline by Indication, 2014 7
Synageva BioPharma Corp. - Pipeline by Stage of Development, 2014 8
Synageva BioPharma Corp. - Monotherapy Products in Pipeline, 2014 9
Synageva BioPharma Corp. - Phase III, 2014 10
Synageva BioPharma Corp. - Preclinical, 2014 11
Synageva BioPharma Corp. - Pipeline by Target, 2014 21
Synageva BioPharma Corp. - Pipeline by Route of Administration, 2014 22
Synageva BioPharma Corp. - Pipeline by Molecule Type, 2014 23
Synageva BioPharma Corp. - Recent Pipeline Updates, 2014 24
Synageva BioPharma Corp. - Dormant Developmental Projects,2014 31
Synageva BioPharma Corp. - Discontinued Pipeline Products, 2014 32
Synageva BioPharma Corp., Subsidiaries 33